Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 1.00 |
| ▸ | PRKCB | P05771 | 11/20 | 0.73 |
| ▸ | PRKCA | P17252 | 6/20 | 0.69 |
| ▸ | PRKCG | P05129 | 4/20 | 0.69 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.60 |
| ▸ | CDK1 | P06493 | 2/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.60 |
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.60 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.60 |
| ▸ | IDH1 | O75874 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354893 | 0.89 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL11937057 | 0.88 | GSK3B (0.78) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL13616209 | 0.88 | GSK3B (0.78) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL2979250 | 0.87 | GSK3B (0.78) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL2986746 | 0.87 | GSK3B (0.78) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL13204273 | 0.87 | GSK3B (0.78) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL11937056 | 0.85 | GSK3B (0.74) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL2984397 | 0.85 | GSK3B (0.82) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL2979403 | 0.85 | GSK3B (0.74) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL2985656 | 0.84 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGCCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4627058-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| EP-4627062-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| US-12188046-B2 | Culture medium, coating matrix and method for expanding midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-01-07 | — | — | US | claimed |
| US-20240352419-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED HEMATOPOIETIC LINEAGE CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-24 | — | — | US | claimed |
| US-20240327788-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-03 | — | — | US | claimed |
| US-20240327787-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-03 | — | — | US | claimed |
| US-20240316196-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-09-26 | — | — | US | claimed |
| US-20240200027-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-20 | — | — | US | claimed |
| WO-2024113352-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED HEMATOPOIETIC LINEAGE CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | claimed |
| WO-2024113358-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | claimed |
| WO-2024113354-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | claimed |
| CN-116121180-A | Media and methods for producing cardiomyocytes from pluripotent stem cells | 安徽中盛溯源生物科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | claimed |
| EP-2550355-B1 | DIRECTED DIFFERENTIATION AND MATURATION OF PLURIPOTENT CELLS INTO HEPATOCYTE LIKE CELLS BY MODULATION OF WNT-SIGNALLING PATHWAY | TAKARA BIO EUROP AB (SE) | 2016-11-16 | — | — | EP | claimed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | claimed |
| US-20130337564-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. | 2013-12-19 | — | — | US | claimed |
| EP-2283114-A2 | TREATMENT OF PLURIPOTENT CELLS | Centocor Ortho Biotech Inc. (US) | 2011-02-16 | — | — | EP | claimed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | claimed |
| WO-2009132068-A2 | TREATMENT OF PLURIPOTENT CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2009-10-29 | — | — | WO | claimed |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4647498-A2 | IMPROVED REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS | Fate Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4627058-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4627061-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4627062-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12415989-B2 | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs | FATE THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12410403-B2 | Methods and compositions for inducing hematopoietic cell differentiation | FATE THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-3805369-B1 | IMPROVED REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS | FATE THERAPEUTICS INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391919-B2 | Culture medium, coating matrix and method for maturing midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| US-12385012-B2 | Methods and compositions for inducing hematopoietic cell differentiation | FATE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4587558-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | Fate Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12365875-B2 | Methods for generating skeletal muscle progenitor cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-22 | — | — | US | disclosed |
| EP-3565887-B1 | METHODS FOR GENERATING SKELETAL MUSCLE PROGENITOR CELLS | UNIV CALIFORNIA (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12351831-B2 | Platform for the induction and maintenance of ground state pluripotency | FATE THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250215396-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250207092-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025091318-A1 | IMPROVED PRODUCTION OF INDUCED MIDBRAIN DOPAMINERGIC PROGENITOR CELLS FROM PLURIPOTENT STEM CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-05-08 | — | — | WO | disclosed |
| US-20250136934-A1 | PRODUCTION OF INDUCED MIDBRAIN DOPAMINERGIC PROGENITOR CELLS FROM PLURIPOTENT STEM CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| US-20250136948-A1 | INDUCTION OF PLURIPOTENT CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-01 | — | — | US | disclosed |
| US-12281329-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12264322-B2 | Minimal volume reprogramming of mononuclear cells | FATE THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12195762-B2 | Induction of pluripotent cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-01-14 | — | — | US | disclosed |
| US-12188046-B2 | Culture medium, coating matrix and method for expanding midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20250002844-A1 | GENERATION AND MAINTENANCE OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2025-01-02 | — | — | US | disclosed |
| US-20240352419-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED HEMATOPOIETIC LINEAGE CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| US-20240344033-A1 | ENDOMETRIAL MODEL, METHOD FOR PREPARING ENDOMETRIAL MODEL, AND ENDOMETRIAL IMPLANTATION MODEL | TOHOKU UNIVERSITY (JP) | 2024-10-17 | — | — | US | disclosed |
| US-20240327787-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240327788-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240316196-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-12054741-B2 | Generation and maintenance of stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240228975-A9 | Methods for Differentiating Endothelial Cells | LUNG BIOTECHNOLOGY PBC | 2024-07-11 | — | — | US | disclosed |
| US-20240228977-A1 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD | FUJIFILM Cellular Dynamics, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4390899-A1 | ENDOMETRIUM MODEL, METHOD FOR PRODUCING ENDOMETRIUM MODEL, AND ENDOMETRIAL IMPLANTATION MODEL | Tohoku University (JP) | 2024-06-26 | — | — | EP | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240200028-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240200027-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| WO-2024113351-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024113358-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024113352-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED HEMATOPOIETIC LINEAGE CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024113354-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| US-20240132851-A1 | Methods for Differentiating Endothelial Cells | LUNG BIOTECHNOLOGY PBC (US) | 2024-04-25 | — | — | US | disclosed |
| EP-2582794-B2 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD | FUJIFILM CELLULAR DYNAMICS INC (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024059584-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11932870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. | 2024-03-19 | — | — | US | disclosed |
| US-20240052317-A1 | Methods for Differentiating Stromal Cells or Pericytes | LUNG BIOTECHNOLOGY PBC | 2024-02-15 | — | — | US | disclosed |
| US-20240052318-A1 | Methods for Differentiating AT2 Cells | LUNG BIOTECHNOLOGY PBC | 2024-02-15 | — | — | US | disclosed |
| US-20240043807-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING SKELETAL MUSCLE | IXCELLS BIOTECHNOLOGIES USA, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20240034999-A1 | IMPROVED REPROGRAMMING, MAINTENANCE AND PRESERVATION FOR INDUCED PLURIPOTENT STEM CELLS | FATE THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20230374460-A1 | Methods for Cardiac Differentiation of Human Induced Pluripotent Stem Cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-23 | — | — | US | disclosed |
| EP-3114214-B1 | IMPROVED REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS | FATE THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230313130-A1 | TROPHOBLAST STEM CELL-LIKE CELLS CAPABLE OF DIFFERENTIATING INTO PLACENTA-CONSTITUTING CELLS, AND METHOD FOR PRODUCING SAME | TOHOKU UNIVERSITY (JP) | 2023-10-05 | — | — | US | disclosed |
| WO-2023138680-A9 | METHOD FOR INDUCING CELL DIFFERENTIATION | 科济生物医药（上海）有限公司 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023138680-A1 | METHOD FOR INDUCING CELL DIFFERENTIATION | 科济生物医药（上海）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| US-20230212518-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-4183873-A1 | TROPHOBLAST STEM CELL-LIKE CELLS CAPABLE OF DIFFERENTIATING INTO PLACENTA-CONSTITUTING CELLS, AND METHOD FOR PRODUCING SAME | Tohoku University (JP) | 2023-05-24 | — | — | EP | disclosed |
| CN-116121180-A | Media and methods for producing cardiomyocytes from pluripotent stem cells | 安徽中盛溯源生物科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11634688-B2 | Methods and compositions for inducing hematopoietic cell differentiation | FATE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2023021591-A1 | ENDOMETRIUM MODEL, METHOD FOR PRODUCING ENDOMETRIUM MODEL, AND ENDOMETRIAL IMPLANTATION MODEL | 国立大学法人東北大学 | 2023-02-23 | — | — | WO | disclosed |
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-3235901-B1 | INDUCTION OF PLURIPOTENT CELLS | SCRIPPS RESEARCH INST (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220325249-A1 | PLATFORM FOR THE INDUCTION & MAINTENANCE OF GROUND STATE PLURIPOTENCY | FATE THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11441126-B2 | Platform for the induction and maintenance of ground state pluripotency | FATE THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220259557-A1 | CELLS CAPABLE OF DIFFERENTIATING INTO PLACENTA-CONSTITUTING CELLS, AND METHOD FOR PRODUCING SAME | UNIV TOHOKU (JP) | 2022-08-18 | — | — | US | disclosed |
| US-11413286-B2 | Producing astrocytes using small molecules | CITY OF HOPE (US) | 2022-08-16 | — | — | US | disclosed |
| US-11413309-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220228125-A1 | REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS | FATE THERAPEUTICS, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220218571-A1 | HYDROGEL DRUG DELIVERY COMPOSITION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-07-14 | — | — | US | disclosed |
| US-20220169980-A1 | MODULATING CELL PROLIFERATION AND PLURIPOTENCY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3985103-A1 | CELLS CAPABLE OF DIFFERENTIATING INTO PLACENTA-CONSTITUTING CELLS, AND METHOD FOR PRODUCING SAME | Tohoku University (JP) | 2022-04-20 | — | — | EP | disclosed |
| US-11268069-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2020211859-A1 | HYDROGEL DRUG DELIVERY COMPOSITION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2020-10-22 | — | — | WO | disclosed |
| US-10294457-B2 | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | TAKARA BIO EUROPE AB (SE) | 2019-05-21 | — | — | US | disclosed |
| US-20180327717-A1 | Methods for Cardiac Differentiation of Human Induced Pluripotent Stem Cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-11-15 | — | — | US | disclosed |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2017178511-A1 | METHOD OF TREATMENT OF PARKINSONISM | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (ES) | 2017-10-19 | — | — | WO | disclosed |
| EP-3231434-A1 | METHOD OF TREATMENT OF PARKINSONISM | Fundacio Centre de Regulacio Genomica (ES) | 2017-10-18 | — | — | EP | disclosed |
| US-20170260503-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-09-14 | — | — | US | disclosed |
| EP-3194569-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | Agency For Science, Technology And Research (SG) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016043666-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-24 | — | — | WO | disclosed |
| US-20150307839-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | TAKARA BIO EUROPE AB (SE) | 2015-10-29 | — | — | US | disclosed |
| EP-2925859-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Takara Bio Europe AB (SE) | 2015-10-07 | — | — | EP | disclosed |
| US-20140199277-A1 | Methods of Treatment of Retinal Degeneration Diseases | Sanges, Daniela (ES) | 2014-07-17 | — | — | US | disclosed |
| EP-2739723-A1 | METHODS OF TREATMENT OF RETINAL DEGENERATION DISEASES | Cosma, Maria Pia (ES) | 2014-06-11 | — | — | EP | disclosed |
| WO-2014083132-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | CELLECTIS SA (FR) | 2014-06-05 | — | — | WO | disclosed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2658966-A2 | DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MULTIPOTENT NEURAL CREST CELLS | University of Georgia Research Foundation, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2580320-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2013020945-A9 | METHODS OF TREATMENT OF RETINAL DEGENERATION DISEASES | COSMA MARIA PIA (ES) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013020945-A1 | METHODS OF TREATMENT OF RETINAL DEGENERATION DISEASES | COSMA MARIA PIA (ES) | 2013-02-14 | — | — | WO | disclosed |
| EP-2554662-A1 | Methods of treatment of retinal degeneration diseases | Pia Cosma, M Maria (ES) | 2013-02-06 | — | — | EP | disclosed |
| WO-2012091978-A2 | DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MULTIPOTENT NEURAL CREST CELLS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2011159726-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2283114-A2 | TREATMENT OF PLURIPOTENT CELLS | Centocor Ortho Biotech Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090304663-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009132068-A2 | TREATMENT OF PLURIPOTENT CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132068-A2 | TREATMENT OF PLURIPOTENT CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-16 | — | — | US | disclosed |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-16 | — | — | US | disclosed |
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-09 | — | — | US | disclosed |
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-09 | — | — | US | disclosed |
| US-7524858-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7524858-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | GSK3B, GSK3A, WNT3A | GSK3B 1/4885PRKCB 45/4885PRKCA 79/4885 |
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCA 30/4885 |
| US-20220218571-A1 | HYDROGEL DRUG DELIVERY COMPOSITION | PTH1R, PHPT1, PTMS | GSK3B 4433/4885PRKCB 2275/4885PRKCA 2291/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | GSK3B 117/4885PRKCB 54/4885PRKCA 375/4885 |
| US-11413286-B2 | Producing astrocytes using small molecules | CHAT, GMFG, DCX | GSK3B 1216/4885PRKCB 953/4885PRKCA 812/4885 |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | WNT3A, FGF2, MEF2D | GSK3B 4/4885PRKCB 236/4885PRKCA 422/4885 |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCA 30/4885 |
| US-20140199277-A1 | Methods of Treatment of Retinal Degeneration Diseases | ALDH1A2, NR2E3, RARB | GSK3B 162/4885PRKCB 172/4885PRKCA 421/4885 |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | KIT, FLT1, HGF | GSK3B 5/4885PRKCB 75/4885PRKCA 121/4885 |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885PRKCB 61/4885PRKCA 93/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | GSK3B 42/4885PRKCB 790/4885PRKCA 343/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | GSK3B 463/4885PRKCB 1377/4885PRKCA 1012/4885 |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD14, HGF | GSK3B 243/4885PRKCB 331/4885PRKCA 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.